

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED
領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

CLARIFICATION ANNOUNCEMENT

**TERM SHEET IN RELATION TO SUBSCRIPTION OF
NEW SHARES UNDER SPECIFIC MANDATE**

Reference is made to the announcement (the “**Announcement**”) of Innovative Pharmaceutical Biotech Limited (the “**Company**”) dated 2 December 2015 in relation to the entering of the Term Sheet by and between the Company and the Subscriber for the Subscription of 600,000,000 new Shares by the Subscriber at the Subscription Price of HK\$1.00 per Share. Unless otherwise defined, capitalized terms used herein shall have the same meaning as ascribed to it in the Announcement.

The Board has come to notice that there are some clerical errors in the Announcement in relation to the details of shareholding of Dr. Mao Yumin in the Company and Dr. Mao’s shareholdings in each of United Gene Holdings Limited, Best Champion Holdings Limited and China United Gene Investment Holdings Limited. As stated in the Announcement, China United Gene Investment Holdings Limited is owned as to 60% by Best Champion Holdings Limited, which is in turn owned as to 33.50%, 33.50% and 33.00% by United Gene Holdings Limited, Ease Gold Investment Limited and Good Links Limited, respectively. United Gene Holdings Limited is wholly owned by Dr. Mao. Ease Gold Investment Limited is wholly owned by Dr. Xie. Good Links Limited is wholly owned by Victory Trend Limited, which is

in turn owned as to 50% by Dr. Mao and as to 50% by Dr. Xie. JNJ Investments Limited is wholly owned by Biowindow Gene Development (Hong Kong) Limited which is in turn wholly owned by United Gene Group Limited. United Gene Group Limited is wholly owned by United Gene Holdings Limited, which is wholly owned by Dr. Mao.

The Board wishes to clarify that, to the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, China United Gene Investment Holdings Limited is owned as to 60% by Best Champion Holdings Limited, which is in turn owned as to 33.50%, 33.50% and 33.00% by United Gene Holdings Limited, Ease Gold Investment Limited and **Victory Trend Limited**, respectively. United Gene Holdings Limited is wholly owned by Dr. Mao Yumin ("**Dr. Mao**"). Ease Gold Investment Limited is wholly owned by Dr. Xie Yi ("**Dr. Xie**"). **Victory Trend Limited** is wholly owned by **Good Links Limited**, which is in turn owned as to 50% by Dr. Mao and as to 50% by Dr. Xie. JNJ Investments Limited is wholly owned by Biowindow Gene Development (Hong Kong) Limited which is in turn wholly owned by United Gene Group Limited. **United Gene Group Limited is owned as to 33.3% and 33.3% by United Gene Holdings Limited and Ease Gold Investment Limited, respectively. United Gene Holdings Limited and Ease Gold Investment Limited are wholly owned by Dr. Mao and Dr. Xie respectively.**

Save for aforesaid clarifications, all other information in the Announcements shall remain unchanged.

By Order of the Board
Innovative Pharmaceutical Biotech Limited
Lee Nga Yan
Executive Director

Hong Kong, 3 December 2015

As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Ms. Lee Nga Yan (executive Director), Dr. Guo Yi (executive Director), Mr. Tang Rong (executive Director), Ms. Xiao Yan (non-executive Director), Ms. Wu Yanmin (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Dr. Zhang Zhihong (independent non-executive Director) and Mr. Wang Rongliang (independent non-executive Director).